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MiR203 mediates subversion of stem cell properties
during mammary epithelial differentiation via
repression of DNP63a and promotes
mesenchymal-to-epithelial transition
AJ DeCastro1, KA Dunphy2, J Hutchinson1, AL Balboni1, P Cherukuri1, DJ Jerry2 and J DiRenzo*,3

During reproductive life, the mammary epithelium undergoes consecutive cycles of proliferation, differentiation and apoptosis.
Doing so relies on the retained proliferative capacity, prolonged lifespan and developmental potency of mammary stem cells
(MaSCs). DNp63a, the predominant TP63 isoform in mammary epithelia, is robustly expressed in MaSCs and is required for
preservation of self-renewing capacity in diverse epithelial structures. However, the mechanism(s) underlying subversion of this
activity during forfeiture of self-renewing capacity are poorly understood. MicroRNAs (miRNAs) govern critical cellular functions
including stem cell maintenance, development, cell cycle regulation and differentiation by disrupting translation of target
mRNAs. Data presented here indicate that expression of miR203, a miRNA that targets DNp63a and DNp63b is activated during
luminal epithelial differentiation and that this pattern is observed in the murine mammary hierarchy. In addition, we present
evidence that the transcription factor Zeb1 represses miR203 expression, thus enhancing DNp63a protein levels. Furthermore,
ectopic miR203 suppresses DNp63a expression, proliferation and colony formation. The anti-clonogenic effects mediated by
miR203 require suppression of DNp63a. In addition, ectopic miR203 promotes mesenchymal-to-epithelial transition and disrupts
activities associated with epithelial stem cells. These studies support a model in which induction of miR203 mediates forfeiture
of self-renewing capacity via suppression of DNp63a and may also have anti-tumorigenic activity through its reduction of EMT
and cancer stem cell populations.
Cell Death and Disease (2013) 4, e514; doi:10.1038/cddis.2013.37; published online 28 February 2013
Subject Category: Experimental medicine

The majority of mammary gland development occurs after
birth and is governed by a precise sequence of hormonal and
morphogenic signals that regulate ductal branching and
elongation of the nascent mammary gland.1 Mammary
organogenesis is driven by the mitotic activity and extravasation of the terminal end bud through the stromal fat pad.
Following mammary organogenesis and near the completion
of puberty, the terminal end bud regresses and the mammary
gland enters a stage of regenerative homeostasis characterized by periodic, successive regenerative cycles composed of
distinct waves of proliferation and cell death.2 This pattern
of regenerative stasis relies on the presence and activity of
mammary stem cells (MaSCs), which have been prospectively isolated from primary mouse and human mammary
epithelial cells.3–6 The epithelial portion of the mammary gland
is a bilayered ductal system. The inner most layer consists of
luminal epithelia that line the mammary ducts and the milkproducing lobuloalveolar units. The basal/myoepithelial layer
separates the luminal epithelia from a basement membrane
and contains cells that co-express DNp63a,7 nestin8 and other

markers associated with stem cell activity. Several studies have
demonstrated that these cells co-enrich with serial mammary
regenerative capacity, indicating that the basal/myoepithelial
layer may represent a specialized MaSC niche.3,4,9
Abundant evidence implicates DNp63 isoforms in preservation of self-renewal and tissue stasis in diverse epithelial
structures, including the mammary gland. Targeted ablation
of DNp63 isoforms leads to broad-spectrum epithelial
hypoplasias characterized by stem cell depletion and ablated
regenerative kinetics.10–12 Although the precise mechanisms
by which DNp63a preserves self-renewing capacity are not
fully understood, substantial evidence indicates that it potently
inhibits cellular senescence.13 In addition, haploinsufficiency
of TP63 confers a premature aging phenotype associated with
a sharp increase in cellular senescence.13–15 In basal breast
cancers and head and neck squamous cell carcinomas,
DNp63a acts as a pro-survival factor and a mediator of chemoresistance that actively represses expression of pro-apoptotic
effectors.16,17 These studies provide compelling evidence that
DNp63a is critical for preservation of replicative capacity,
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prolonged life span and survival that are characteristic of adult
and cancer stem cells. They further suggest that specific
mechanisms exist to subvert these activities during lineage
commitment and cellular differentiation.
MicroRNAs (miRNAs) are a class of endogenous small RNA
molecules that are approximately 22 nucleotides in length.18
MiRNAs govern diverse cellular activities including proliferation, apoptosis, differentiation, development and tumorigenesis by targeting the RNA-induced silencing complex to the
30 -UTR of target mRNAs.19,20 MiR203 was identified as a
stemness inhibiting miRNA that is highly expressed in the
epidermis where it targets a and b isoforms of TP63 to promote
epidermal differentiation.21,22 In addition to its role in normal
epithelial biology, miR203 has also been shown to be
aberrantly expressed in several types of human cancers
including bladder, colon, pancreatic, liver, prostate and
lung.23–28 Interestingly, miR203 is repressed by the transcriptional repressor zinc-finger E-box binding homeobox 1 (ZEB1),
a repressor of multiple key mediators of epithelial differentiation29 and a potent activator of epithelial-to-mesenchymal
transition (EMT).30 EMT is a key developmental program that
can be re-activated during cancer development and has been
linked to tumor invasion, metastasis and chemo-resistance.31
In addition, cancer cells have been reported to utilize EMT to
acquire cancer stem cell properties in part through the
modulation of miRNAs.32–34 These reports implicate miRNAs
as mediators of EMT, stemness and the acquisition of an
aggressive cancer phenotype.33,34 These findings, coupled to
reports linking DNp63a to MaSC renewal and breast cancer
aggression suggest that miR203 may have important roles in the
mammary regenerative hierarchy as well as in breast cancer.
The goal of this study was to determine the functional
significance of miR203 in MaSC activity and luminal epithelial
cell fate in the mammary gland. Results indicate that
expression of miR203 is induced during lactogenic differentiation and increases during luminal epithelial differentiation.
Data presented here indicate that in mammary epithelia,
miR203-mediated suppression of DNp63a reduces proliferation, clonogenic potential and transcriptional suppression of
HBP1, a pro-differentiation gene transcriptionally repressed
by DNp63a.35 In a panel of mammary epithelial and breast
cancer cell lines, miR203 expression correlates with the
degree of luminal differentiation, as it is lowest in basal/triple
negative and highest in luminal-like breast cancer cell lines.
Finally, ectopic miR203 expression is able to mediate a
mesenchymal-to-epithelial transition (MET) that was associated with a reduction in the cancer stem cell population
(CD44 þ CD24  ) and an increase in the expression of the
luminal cell marker CD24. Together, these studies suggest
that miR203 is a potent stem cell regulator and has a
significant role in the acquisition of luminal epithelial cell fate
through the forfeiture of MaSC activity in the normal mammary
gland and breast cancer stem cells.

Results
Expression of miR203 correlates with differentiation in
the mammary epithelium. Substantial evidence indicates
that DNp63a is required for preservation of MaSCs. However,
Cell Death and Disease

the mechanism(s) by which this activity is subverted during
forfeiture of self-renewing capacity and developmental
commitment are not well understood. MiR203 directly targets
sequences within exon 15 of TP63 that encode the 3’UTR of
a and b isoforms.22 This finding coupled to the fact that
DNp63a is required for MaSC preservation suggests that
increased expression of miR203 may promote differentiation
in the mammary regenerative hierarchy. To test this, enriched
fractions of MaSCs (Lin  /CD24 þ /CD29high/CD61 þ ), luminal
progenitors (Lin  /CD24 þ /CD29low/CD61 þ ) and mature luminal epithelia (Lin  /CD24 þ /CD29low/CD61  ) were isolated
(Figure 1a) and analyzed for expression of miR203.
Cytokeratin profiling of these fractions revealed that Lin  /
CD24 þ /CD29low/CD61  fractions were enriched for the
luminal epithelial cytokeratins KRT18 and KRT19
(Supplementary Figure S1a), whereas Lin  /CD24 þ /
CD29high was highly enriched for expression of basal
epithelial markers, KRT14 and KRT5 (Supplementary
Figure S1b). In addition, GATA3 expression was highest
(Supplementary Figure S1c) in mature luminal epithelia
(Lin  /CD24 þ /CD29low/CD61  ), which is consistent with
previous studies indicating that expression of CD61 segregates luminal epithelial cells,35 and that this progression
requires GATA3.36,37 Analysis of miR203 levels indicated a
sharp increase in luminal progenitors and differentiated
luminal epithelial cells relative to the enriched MaSC fraction
(Figure 1b). Previous studies have implicated Zeb1 as a
potent repressor of miR203 and other miRNAs, and can
promote tumorigenic capacity by maintaining self-renewal
capacity.38 Consistent with these findings, Zeb1 expression
was highest in the enriched fractions of MaSCs and declined
in committed populations (Figure 1c). To determine if the
observed increase in miR203 correlated with a decline in
DNp63a protein levels, Lin  /CD24 þ /CD29high/CD61 þ cells
and Lin  /CD24 þ /CD29low/CD61 þ cells, which enrich for
mammary epithelial stem and luminal epithelial progenitor
cells, respectively, were stained for total p63. Results indicate
that p63 is robustly expressed in the enriched fractions of
MaSCs and undetectable in the luminal progenitors
(Figure 1d). Finally HBP1, a pro-differentiation HMG-box
transcriptional regulator39,40 whose expression is repressed
by DNp63a was observed to increase with differentiation
(Figure 1e). Together, these data support a model in which
Zeb1 represses miR203 expression thereby preserving
DNp63a expression in MaSCs and that this repression is
relieved during the loss of self-renewing capacity. Consistent
with this model, we noted a strong correlation between
miR203 levels and the degree of differentiation in breast
cancer cell lines (Figure 1f and Supplementary Figure S1D).
MiR203-mediated suppression of DNP63a is required for
lactogenic differentiation. The previous data demonstrate
a correlation between miR203 expression and differentiation
in the mouse mammary epithelium as well as in breast
cancer. To determine if miR203 expression is induced during
luminal epithelial differentiation and to determine the role of
Zeb1 in this process we adopted an established luminal
differentiation system in which the immortalized murine
mammary epithelial cell line, HC11 is first deprived of EGF
and then treated with dexamethasone, insulin and prolactin
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Figure 1 Expression of miR203 correlates with differentiation in the mammary epithelium. (a) Fluorescence-activated cell sorting (FACS) of negative lineage selected
mammary epithelial cells excised from the mouse mammary gland and labeled with CD29, CD24 and CD61. Labeled mammary epithelial cells were gated for isolation of
MaSCs, luminal progenitor and differentiated luminal cell fractions based on CD29, CD24 and CD61 status. (b) qRT-PCR analysis of isolated mammary cells fractions for
detection of mature miR203 expression. (c) Total RNA was isolated from mammary cell fractions for qRT-PCR analysis on ZEB mRNA expression. (d) Immunofluorescent
staining against P63 from mammary epithelial stem cells (left) and luminal mammary cells (right) applied to glass microscope slides. (e) qRT-PCR analysis of isolated
mammary cell fractions for detection of HBP1 mRNA (transcriptionally repressed by DNP63a). (f) Mature miR-203 expression levels normalized to SnU6 from RNA lysates of
10 mammary and breast cancer cell lines using two-step TaqMan assays. All data are means±S.E.; n ¼ 2, P-values are indicated
Cell Death and Disease
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(DIP).41 These cultures undergo lactogenic differentiation
and express high levels of b-casein in response to EGF
withdrawal and treatment with DIP (Figure 2e). Analysis of
cells treated with vehicle or DIP for 72 h revealed that DIP
caused decreased expression of Zeb1 (Figure 2a), increased
expression of miR203 (Figure 2b), suppression of DNp63a
protein (Figure 2c), while DNp63a mRNA remained
unchanged (Supplementary Figure S2), and increased
expression of HBP1 (Figure 2d). These results are consistent
with the patterns of gene expression observed in the murine
mammary epithelial hierarchy (Figure 1). They also suggest
that the induction of HBP1 and b-casein may require
suppression of DNp63a. To test this, DNp63a was expressed
with a heterologous 30 UTR that is insensitive to miR203 in
HC11 cells and treated with vehicle or DIP. QRT-PCR-based
analysis indicated that the DIP-dependent induction of HBP1
was disrupted by ectopic DNp63a (Figure 2f). This result is
consistent with previous studies indicating that HBP1 is
directly repressed by DNp63a.35 Similarly, DIP-dependent
luminal epithelial differentiation, as measured by induction of
b-casein, was disrupted by ectopic DNp63a indicating that
suppression of DNp63a is required for DIP-induced luminal
differentiation (Figure 2g). Together, these results support a
model in which induction of miR203 and suppression of
DNp63a expression are required for luminal epithelial
differentiation in the DIP-induced HC11 model system
(Figure 2h).
MiR203 induces G0/G1 arrest and blocks colony formation capacity that is rescued by DNp63a. To determine if
induction of miR203 associated with mammary epithelial
differentiation mediates repression of DNp63a and forfeiture
of self-renewal; miR203 was transfected into two immortalized mammary epithelial cells (IMECs), IMEC and HC11,
both of which have features of MaSCs including high levels of
DNp63a. Western analysis of transfectants revealed that
miR203 significantly reduced expression of DNp63a in
IMECs and HC11 cells (Figure 3a). In these studies, it was
also noted that transfection of miR203 but not miR-CON
(control) resulted in a substantial reduction in cell number in
the HC11 cultures within 48 h of transfection (Figure 3b).
Similar, but less dramatic results were observed in IMECs
(data not shown), which is likely due to the slower
proliferation rates of IMECs. This observation coupled to
studies indicating that DNp63a is required for retention of
proliferative potential,11 suggested that the reduction in cell
number within miR203 transfectants may be the result of a
proliferative arrest. To test this, HC11 cells were transfected
with miR-CON or miR203 and cell cycle distribution was
analyzed by propidium iodine staining at 72 h after transfection. Results indicated a substantial accumulation of cells in
the 2N state (Figure 3c), suggesting that cells had either
undergone proliferative arrest or had become quiescent. This
result suggests that miR203 has a potent anti-proliferative
effect, which is consistent with the observed increase in
miR203 expression during cellular differentiation. To determine if the anti-proliferative effects of miR203 required
suppression of DNp63a, IMEC cells were infected with
retroviruses programmed to express nothing (pLPC) or the
open reading frame of DNp63a (pLPC-DNp63aORF), which
Cell Death and Disease

renders it resistant to miR203-mediated repression, and then
transfected with miR-CON or miR203. Results indicated that
ectopic miR203 prevented colony formation (Figure 3d).
Importantly, the anti-clonogenic effect of miR203 was
potently rescued by expression of DNp63a, indicating that
miR203 is able to suppress DNp63a in a manner that is
consistent with forfeiture of proliferative capacity in mammary
epithelium.
MiR203 opposes the activities of normal and cancer
stem cells. The ability of miR203 to repress DNp63a
expression (Figure 3a) and disrupt DNp63a-mediated clonogenicity (Figure 3d) suggests a role in the forfeiture of stem
cell properties. A common feature of epithelial stem cells is
the ability to form multicellular structures that can proliferate
in an attachment-independent manner. These structures,
referred to as mammospheres, are derived from MaSCs and
this culture system has been used to enrich for tumorigenicity
within breast tumors and breast cancer cell lines.42 The
ability to enrich for subpopulations with stem cell features
coupled to the observed increase in miR203 levels in nonstem populations (Figures 1 and 2) suggested that miR203
levels would be reduced in mammospheres relative to their
parental monolayer culture. To test this, miR203 levels were
measured in MCF7 cells derived from monolayer and
mammosphere cultures. Results indicated miR203 levels
are reduced in the mammospheres (Figure 4a). To determine
the effects of miR203 on mammosphere forming capacity,
IMEC cells were either mock transfected or transfected with
miR-CON or MiR203 and 25 000 cells from each transfection
were cultured under low attachment conditions for 14 days.
Visual inspection of the cultures indicated that ectopic
miR203 completely ablated mammosphere formation
(Figure 4b) and this was quantified by counting cells following
gentle trypsinization of the mammospheres (Figure 4b).
These data suggest that miR203 is sufficient to disrupt
mammosphere forming capacity, which is consistent with a
model in which miR203 subverts the stem cell phenotype.
Several studies have demonstrated a substantial enrichment
of stem cells within the CD44 þ /CD24  fraction of breast
tumors and breast cancer cell lines.43,44 To determine the
effects of miR203 on this feature of stem cells, IMEC cells
were mock transfected or transfected with miR-CON or
miR203 and CD44 þ /CD24  fractions were quantified by
flow cytometry. IMECs were chosen for this study because of
their high proportion of CD44 þ /CD24  cells and their low
endogenous levels of miR203. Results indicated that ectopic
miR203 caused a reduction in the CD44 þ /CD24  population
from 97.5 to 79.3% relative to the miR-CON transfectants
(Figure 4c). This reduction was due in large part to an
increase in CD44 þ /CD24 þ cells suggesting that miR203
caused an increase in the number of cells that had forfeited
self-renewing capacity. Together, these data indicate that
miR203 is sufficient to subvert the phenotypic properties of
MaSCs.
MiR203 is negatively regulated by Zeb1 and is inversely
expressed in mammary and breast cancer cell lines. The
previous data (Figures 1 and 2) coupled to a recent study
indicating that Zeb1 promotes a stem cell phenotype via
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Figure 2 Modulation of the ZEB1-miR203-DNP63a pathway during luminal epithelial differentiation. The mouse mammary epithelial cell line HC11was plated and on
confluence were then withdrawn of EGF for 48 h. Cells were then treated with differentiation inducing media (DIP) for 72 h. Cells were collected for RNA and protein analysis.
Total RNA was isolated from cells for qRT-PCR analysis to detect (a) ZEB1 mRNA, (b) mature miR203, (d) HBP1 mRNA and (e) b-casein mRNA. (c) Western blot analysis
was performed on HC11 protein lysates to detect DNP63a protein expression levels. (f and g) HC11 cells were treated with DIP differentiating media for 72 h in the presence or
absence of an adenovirus expressing the ORF of DNP63a (lacking the UTR’s), which cause resistance to miR-203 translational inhibition. qRT-PCR analysis were performed
on total RNA lysates to detect mRNA expression levels of HBP1 (f), and b-casein (g). Data are means±S.D.; n ¼ 3, *Po0.00004, **Po0.02 and #Po0.005. (h) Schematic
of the regulatory pathway that mediates the downregulation of DNP63a protein during luminal mammary cell differentiation

transcriptional repression of miRNAs suggest that transcriptional repression of miR203 by Zeb1 promotes DNp63a
expression.38 To test this prediction and determine its
relevance to breast cancer, a panel of immortal and
transformed mammary epithelial cell lines representing
poorly differentiated to well differentiated states was evaluated for Zeb1 mRNA levels and miR203 levels. Results
indicate that Zeb1 expression is highest in poorly differentiated cells and miR203 expression is highest in welldifferentiated cells (Figure 5a). This inverse correlation
suggests that Zeb1 promotes expression of DNp63a via
repression of miR203. Si-RNA-mediated suppression of
Zeb1 resulted in a robust increase in miR203 levels
(Figure 5b) and sharply lowered levels of DNp63a protein
(Figure 5c). Conversely, gain-of-function studies in MCF10A

cells, which were chosen for their low levels of Zeb1,
indicated that ectopic Zeb1 repressed expression of
miR203 (Figure 5d) and increased DNp63a levels
(Figure 5e). Together, these studies support a model in
which Zeb1-mediated suppression of miR203 enhances
expression of DNp63a.
MiR203 promotes MET. The observation that Zeb1 actively
represses miR203 coupled to its role in promoting EMT
suggests that miR203 may be differentially expressed during
this transition. To test this, CDb-Geo cells, a derivative of
HC11 cells, were treated with TGFb to induce EMT.45
Immunofluorescent analysis of these cells indicated that
TGFb treatment resulted in a sharp decrease in E-cadherin
expression, a hallmark feature of EMT (Figure 6a). Post-EMT
Cell Death and Disease
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cells, which suggest that it may be a contributing factor to the
reduction of miR203 expression (Figure 6b). This observation suggests that suppression of miR203 levels is required
for EMT and that miR203 may oppose EMT. Consistent with
this prediction, transfection of miR203 into IMECs resulted in
a sharp induction of E-cadherin and a corresponding
decrease in vimentin demonstrating that miR203 opposes
EMT and promotes MET (Figure 6c). These results propose
that miR203 may restrict cell motility, a hallmark of EMT. To
test this, MDA-MB-231 cells, which display features of EMT
including enhanced cell motility, were cultured to confluence
and mock transfected, or transfected with miR-CON or
miR203. At 24 h after transfection, uniform scratches were
etched onto the monolayer and cells were visually monitored
over 48 h to observe the rates at which cells re-colonize the
scratch. Digital imaging (Figure 6d) and quantification
(Figure 6e) indicated that transfection of miR203 potently
inhibited the ability of cells to recolonize the scratch,
suggesting that miR203 restricts cell motility. Together, these
data indicate that expression of miR203 is reduced in cells
that have undergone EMT and that miR203 is sufficient to
promote MET and reduce cell motility.
Discussion

Figure 3 MiR203 induces G0/G1 arrest and blocks colony formation capacity in a
manner that is rescued by DNP63a. (a) Western blot analysis of protein lysates from
IMEC (left) and HC11 (right) cells transiently transfected with mature miR203 (60 nm) for
48 h and probed with an anti-P63 antibody (4A4). (b) 10  Phase contrast microscopy
of HC11 cells transiently transfected with mature miR203 (60 nm) for 72 h. (c) PI cell
cycle analysis was performed via flow cytometry of HC11 cells transiently transfected
with mature miR203 for 72 h (cells were treated with nocodizole to synchronize cells
before PI cell cycle analysis). (d) IMEC cells were either infected with an empty
retrovirus or a retrovirus expressing the open reading frame of DNP63a (pLPCDNP63aORF) and then transiently transfected with either a miR-control or mature
miR203 (60 nm) and then plated for colony formation assay. Colonies were stained with
crystal violet and imaged. All experiments were performed in triplicate (n ¼ 3)

cells expressed significantly less miR203 compared with
untreated CDb-Geo cells (Figure 6b). Conversely, Zeb1
mRNA expression was increased in post-EMT CDb-Geo
Cell Death and Disease

Data presented here support a model in which induced
expression of miR203 is an early event in the mammary
epithelial hierarchy that mediates forfeiture of self-renewing
capacity by suppressing DNp63a. Our data indicate that
miR203 correlates with differentiation in breast cancer cell
lines and in the mammary epithelial hierarchy. In addition,
miR203 expression increases in response to induction of
differentiation and that differentiation depends on suppression
of DNp63a. Importantly, ectopic expression of miR203 in
HC11 and IMEC cells was not sufficient to induce differentiation as indicated by b-casein expression (data not shown),
however, it did suppress DNp63a, which lead to induction of
the pro-differentiation gene HBP1 (Supplementary Figures 3A
and B). These data are consistent with miR203 functioning
early in the differentiation pathway to mediate the forfeiture of
self-renewing capacity. In addition, gain-of-function studies
indicate that miR203 is anti-proliferative, disrupts self-renewal
and is potently anti-clonogenic. This latter feature is rescued
by ectopic DNp63a, indicating that this effect is mediated via
suppression of DNp63a. Suppression of miR203 correlates
with expression of Zeb1, which is a negative prognostic factor
in breast cancer. These findings suggest a mechanism by
which Zeb1 contributes to poor prognosis and suggests that
miR203 may function as a tumor suppressor that promotes an
orderly progression through the mammary epithelial hierarchy. Additional studies will be necessary to determine if
miR203 has tumor-suppressor activity.
We have described a regulatory pathway that is differentially activated during cellular differentiation (Figure 2 and
Supplementary Figure 3C). In the undifferentiated stem and
progenitor cells, expression of Zeb1 suppressed miR203
expression thereby increasing DNp63a protein and suppressing expression of HBP1 (Figures 1 and 2). Conversely, in a
differentiated state, Zeb1 expression is repressed resulting
in increased miR203 levels, suppression of DNp63a and
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Figure 4 MiR203 opposes the activities of normal and cancer stem cells. (a) RT-qPCR analysis of total RNA for mature miR-203 expression levels isolated from parental
(ML) and secondary mammospheres (21-MS) of MCF-7 cells (mammospheres enrich for stem cells). Data are means±S.D.; n ¼ 3, asterisk indicates Po0.05.
(b) Mammosphere formation assay of IMEC cells transiently transfected with miR-control of mature miR203 (60 nM); 25 000 cells were then transferred to low binding plates
and grown for 14 days. Mammospheres were trypsinized and total cells were counted per experimental group (left), Representative 10  phase contrast images of
mammospheres from each experimental group (right). Data are means±S.E.; n ¼ 3, P-values are indicated. (c) Flow cytometric analysis of IMECs labeled with the stem cell
enrichment markers CD24 and CD44. IMECs were transiently transfected with miR-control or mature miR203 (60 nM). Seventy-two hours after transfection, cells were labeled
with CD24-PE and CD44-FITC and analyzed via flow cytometry. Representative flow cytometry density plots of CD24 versus CD44 from experiment conduced in triplicate

increased expression of HBP1 (Figure 2). HBP1 has been
previously identified as a tumor suppressor in breast cancer,46
a target of transcriptional repression of DNp63a39 and a
mediator of differentiation.47 It is also a potent inhibitor of Wnt
signaling, which maintains self-renewal, suggesting that
induction of HBP1 downstream of miR203 may contribute to
the forfeiture of self-renewal.46,48 In addition, in the HC11
model of luminal differentiation, HC11 cells are grown in the
undifferentiated state via EGF treatment. Following EGF
withdrawal, HC11 cells are induced to a committed predifferentiated progenitor state, which are then committed to a
complete differentiated state by addition of DIP. We observed
initial induction of miR203 as early as the pre-differentiated
state on EGF withdrawal (data not shown); which supports
miR203 as an early mediator in the differentiation pathway,
most likely to facilitate the forfeiture of stem cell properties.
Furthermore, in a recent study, miRNA targeted gene profiling
identified overlapping signatures between the undifferentiated
stem cell-like HC11 state and poor prognosis where patients
exhibiting a SC-like miRNA profile had lower survival rates.49
It will therefore be of interest to determine if expression of
miR203 correlates with a favorable prognosis in breast cancer
patients. In addition, as miR203 targets DNp63a and BMI1,
another protein implicated in the preservation and activity of
stem cells, it will be of interest to determine if miR203

expression can identify patients at low risk for breast cancer
recurrence.
We present evidence that ablation of Zeb1 leads to
increased expression of miR203 and suppression of DNp63a.
Coupled to several studies implicating Zeb1 in activation of
pro-EMT transcriptional programs,38,50 and tumor cell dedifferentiation,29 our study implicates miR203 in the specification of epithelial cell fate. Further, it suggests that miR203
mediates forfeiture of cellular plasticity, which is a hallmark of
EMT and cancer stem cell behavior.51 In addition, ZEB1 is
overexpressed in various cancer cell lines, including breast,
and has been shown to promote tumor cell migration and
metastasis.52 Similarly, a miRNA expression profiling study of
human metastatic cancers and paired primary tumors found
miR203 to be consistently underexpressed in the metastatic
tissue,53 further implicating a relationship between ZEB1
regulation of miR203 and tumor invasiveness and metastasis.
Coupled with data presented in this study, miR203 appears to
have an anti-tumorigenic role, and its expression may
coincide with metastatic potential.
Finally, we show that miR203 was sufficient to induce a
MET and a decrease in the breast cancer stem cell population
(Figures 5 and 6). Of interest, ectopic miR203 significantly
increased the expression of the luminal cell surface marker
CD24, further implicating miR203 as a mediator of luminal cell
Cell Death and Disease
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Western blot analysis. Total cell protein extracts were obtained using
NETN lysis buffer (100 mM Tris-Cl (pH 7.8), 1 mM EDTA, 100 mM NaCl, and 0.1%
Triton X-100) supplemented with protease and phosphatase inhibitors (Roche,
Branchburg, NJ, USA). Protein concentrations were measured by Lowry protein
assay and 10 mg of protein per sample was resolved on an 8% SDSpolyacrylamide gel and transferred onto a PVDF membrane. Membranes were
blocked with TBST 5% non-fat dry milk for 1 h at room temperature, incubated with
primary antibodies overnight at 4 1C, washed and incubated for 1 h at room
temperature with horseradish peroxidase-conjugated secondary antibody.
Antibodies. For western blotting, mouse anti-p63 (4A4) (LabVision, Kalamazoo, MI, USA; 1/500 dilution), mouse anti-b-actin (Cell Signaling, Boston, MA,
USA; 1/1000 dilution) antibodies were used. For sorting primary mammary
epithelial cells from mice, antibodies against mouse antigens include CD24-PE
(BD Biosciences, San Jose, CA, USA; 1/100 dilution), CD29-FITC (BD
Biosciences; 1/100 dilution), and CD61-APC (Invitrogen, Grand Island, NY,
USA; 1/100 dilution). Secondary antibodies used were anti-mouse IgG (Sigma, St.
Louis, MO, USA; 1/10 000 dilution). For flow cytometry experiments, FITCconjugated mouse anti-human CD44 and PE-conjugated mouse anti-human CD24
(BD Biosciences) were used.
RT-qPCR. RNA was isolated using RNeasy mini kit or miRNeasy mini kit for
mRNA and miRNA, respectively (Qiagen, Valencia, CA, USA) as per the
manufacturer’s protocol. For mRNA analysis, RNA (1 mg) was reverse transcribed
using random hexamers and Q-PCR was conducted using the SsoFast Eva Green
master mix (Bio-Rad, Hercules, CA, USA). The 2  DDCT method was used for
quantification of gene expression changes. Relative changes were normalized to
glyceraldehyde-3-phosphate dyhydrogenase or b-actin for differentiation experiments. The relative expression levels of miR203 were measured using a two-step
Taqman assay according to the manufacturer’s protocol. RNA (10 ng) for miRNA
analysis was reverse transcribed using Taqman Reverse Transcriptase Kit
(Applied Biosystems, Carlsbad, CA, USA) for miR203 or the internal control SnU6.
Taqman real-time PCR was prepared using Universal PCR Master Mix No
AmpErase UNG (Applied Biosystems) and specific primers for miR203 and SnU6
from Taqman MicroRNA Assays (Applied Biosystems). Expression levels of
miR203 were based on the amount of the target message relative to that of the
SnU6 transcript as a control to normalize the initial input of total RNA.

Figure 5 MiR203 is negatively regulated by ZEB1 and is inversely expressed in
mammary and breast cancer cell lines. (a) Total RNA was isolated from five
mammary and breast cancer cell lines and qRT-PCR analysis to detect ZEB1
mRNA and mature miR203 was performed. (b and c) IMEC cells were transiently
transfected with siRNA against ZEB1 or scramble control (60 nm) and harvested
48 h later for qRT-PCR analysis on mature miR203 (b) and western blot analysis
using an anti-P63 antibody (c). (d and e) MCF10A cells were transiently transfected
with an empty mammalian expression plasmid (pCDNA-CTR) or one encoding
murine Zeb1 (pCDNA-Zeb1). Cells were collected 72 h after transfection and
analyzed using qRT-PCR for mature miR203 detection and western blot using antiZeb1 and anti-P63 antibodies. Data are means±S.D.; n ¼ 3

fate and commitment. It is possible that miR203 suppression
is a mechanism by which cancer cells can acquire an EMT,
stem cell-like phenotype in order to garner an aggressive, prometastatic phenotype. Taken together, we have described
miR203 as a potent inhibitor of stem cell function through the
targeted inhibition of DNp63a, which may have a role in breast
cancer development.
Materials and Methods
Cell culture. A total of 10 mammary epithelial or breast cancer cell lines (MDAMB-231, MDA-MB-468, SUM149, SKBR3, BT20, MCF10A, HCC1937, ZR75,
T47D and MCF7) were examined in this study. Each was maintained according to
ATCC guidelines. Establishment and maintenance of the IMEC line has been
previously described.7,54
Cell Death and Disease

MiRNA analysis and transfections. For miRNA overexpression,
2.5  105 cells per well were seeded in six-well-plates. Pre-miR (Applied
Biosystems) mimicking mature miR203 or control nonspecific miRNA (Pre-miRnegative control NC#1; Applied Biosystems) was transfected at 60 nM final
concentration into cells using Oligofectamine transfection reagent (Invitrogen). At
24 h after transfection, cells were assessed for DNp63a protein content via
western blot. For cell cycle analysis of HC11 cells transfected with Pre-miR203 or
control, cells were split 1 : 4, 48 h after transfection and subsequently collected for
propidium iodide (PI) staining 72 h after transfection. For experiments involving
ZEB1 knockdown, IMEC cells were transfected with either scramble si-control or a
siRNA targeted against ZEB1 at 60 nM final concentration using Oligofectamine
Transfection Reagent (Invitrogen). For ZEB1 overexpression experiments,
MCF10A cells were transfected with an empty control mammalian expression
plasmid (pCDNA-CTR) or one encoding murine ZEB1 (pCDNA-ZEB1) using
Lipofectamine 2000 Transfection reagent (Invitrogen). Cells were harvested 48
and 72 h after transfection for analysis.
Lactogenic differentiation of HC11 cells. The prolactin-responsive cell
line, HC11, was split 1 : 5 and maintained in RPMI 1640 medium containing 10%
fetal bovine serum, L-glutamine, 5 mg/ml insulin and 10 ng/ml epidermal growth
factor. For induction of differentiation the cells were grown to confluence and then
kept in the above media without EGF for 48 h to induce competence.
Differentiation-competent cells were incubated in RPMI 1640 medium containing
10% fetal bovine serum, L-glutamine, 5 mg/ml insulin and supplemented with
100 nM dexamethasone, 5 mg/ml insulin, in the presence or absence of 5 mg/ml
prolactin for 72 h.
Cell cycle distribution analysis. Cells were collected at approximately
60% confluence and fixed in 70% ethanol for 48 h at  20 1C. Cells were washed
in PBS supplemented with 3% FBS and resuspended in buffer (PBS, 0.1% Triton
X-100, DNase-free RNAse-A 100 mg ml  1) with 50 mg ml  1 of PI. Following
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Figure 6 MiR203 promotes MET. (a) Immunofluorescent images stained for E-cadherin (green), b-actin (red) and DAPI for nuclear localization of CDb-Geo cells that have
been treated with vehicle (control) or TGFb. (b) Total RNA was isolated from CDb-Geo cells that have not (  ) or have undergone EMT ( þ ) and qRT-PCR analysis was
performed to measure Zeb1 mRNA and mature miR203 expression levels. (c) Western blots of protein lysates from IMEC cells transiently transfected with miR-control or
mature miR203 (60 nm) for 48 h were probed with anti-E-cadherin and anti-vimentin antibodies. (d) MDA-MB-231 cells were transiently transfected with miR-control or mature
miR203 (60 nm) and plated for wound healing assay. At 90% confluence the cells were scratched and then observed for 48 h to measure closure of the wound. 10  phase
contrast microscopy of wound healing assay at 0, 24 and 48 h after scratch (c) and quantification of re-migration of the cleared space between experimental controls (e).
All experiments were performed in triplicate (n ¼ 3) and data are means±S.D.

incubation at 37 1C for 1 h, PI fluorescence distribution of 20 000 single cells was
measured with a FACScan Flow Cytometer (BD Biosciences). Subsequent data
were analyzed with FlowJo cell cycle software (Ashland, OR, USA).

antibodies against mouse antigens and include CD24-PE, CD29-FITC and CD61APC. FACS analysis and cell sorting were performed using a FACS Aria (BD
Biosciences).

Mammosphere formation. Human IMECs were transfected with 60 nM
final concentration of miR203, miR-control or mock control. At 24 h after
transfection, cells were trypsinized and seeded at 25 000 cells per 10 cm plate
coated with poly-2-hydroxyethyl methacrylate (20 mg/ml). Cells were grown in low
binding conditions for 14 days and collected for analysis.

Flow cytometry analysis. Cells were trypsinized and washed once with
PBS containing 2% FBS (wash buffer), and resuspended in 50 ml of wash buffer.
Fluorochrome-conjugated monoclonal antibodies against human CD44-FITC and
CD24-PE or their respective controls were added to the cell suspension and
incubated in the dark at 4 1C for 35 min. The labeled cells were then washed in
wash buffer and resuspended in 500 ml PBS and subsequently analyzed on a
MACSQuant Analyzer (Miltenyi Biotec, Auburn, CA, USA).

Retroviral infection and colony formation assay. Platinum-A retroviral packaging cell line (Cell BioLabs Inc., San Diego, CA, USA) was transfected
with the mammalian retroviral expression vector pLPC (Addgene, Cambridge, MA,
USA) containing the open reading frame of DNP63aORF, or empty vector control
(pLPC). At 24 h after transfection, viral titers were collected and used to infect
IMECs. Seventy-two hours after infection; IMECs were transfected with miR203 or
nonspecific miR-control. At 24 h after transfection, cells were plated at colony
formation density (1000 cells per well in a six-well tissue culture plate). Colonies
were stained using crystal violet 12 days after plating cells.
Mammary cell preparation and FACS cell sorting. Dissection and
single cell suspension of the thoracic and inguinal mammary glands from virgin
female mice were prepared as previously described.9 Negative lineage selection
was performed on the RoboSep fully automated cell separator (StemCell
Technologies, Vancouver, BC, Canada) using the mouse Easy-Sep MaSC
enrichment kit (StemCell Technologies). Cells were subsequently labeled with

Statistical analysis. Statistical analyses were performed using Students’
t-test. A P-value o0.05 was considered significant.
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